Department of Endocrinology ASO/EASO COM, King's College Hospital NHS Foundation Trust, Denmark Hill, London, UK.
Quebec Heart and Lung Institute, Laval University, Canada.
Obes Rev. 2024 Aug;25(8):e13759. doi: 10.1111/obr.13759. Epub 2024 May 6.
To evaluate the impact of bariatric surgery on the pharmacokinetic (PK) parameters of orally administered medications and supplements.
Systematic searches of bibliographic databases were conducted to identify studies. Pooled effect estimates from different surgical procedures were calculated using a random-effects model.
Quantitative data were synthesized from 58 studies including a total of 1985 participants. Whilst 40 medications and 6 supplements were evaluated across these studies, heterogeneity and missing information reduced the scope of the meta-analysis to the following medications and supplements: atorvastatin, paracetamol, omeprazole, midazolam, vitamin D, calcium, zinc, and iron supplements. There were no significant differences in PK parameters post-surgery for the drugs atorvastatin and omeprazole, and supplements calcium, ferritin, and zinc supplements. Paracetamol showed reduced clearance (mean difference [MD] = -15.56 L/hr, p = 0.0002, I = 67%), increased maximal concentration (MD = 6.90 μg/ml, p = 0.006, I = 92%) and increased terminal elimination half-life (MD = 0.49 hr, p < 0.0001, I = 3%) post-surgery. The remaining 36 medications and 2 supplements were included in a systematic review. Overall, 18 of the 53 drugs and supplements showed post-operative changes in PK parameters.
This study demonstrates heterogeneity in practice and could not reach conclusive findings for most PK parameters. Prospective studies are needed to inform best practice and enhance patient healthcare and safety following bariatric surgery.
评估减重手术对口服药物和补充剂的药代动力学(PK)参数的影响。
系统检索文献数据库以确定研究。使用随机效应模型计算来自不同手术程序的汇总效应估计值。
从包括 1985 名参与者的 58 项研究中综合了定量数据。虽然这些研究评估了 40 种药物和 6 种补充剂,但异质性和信息缺失限制了荟萃分析的范围,仅包括以下药物和补充剂:阿托伐他汀、对乙酰氨基酚、奥美拉唑、咪达唑仑、维生素 D、钙、锌和铁补充剂。手术后药物阿托伐他汀和奥美拉唑以及补充剂钙、铁蛋白和锌补充剂的 PK 参数没有显着差异。对乙酰氨基酚的清除率降低(平均差异 [MD] = -15.56 L/hr,p = 0.0002,I = 67%),最大浓度增加(MD = 6.90 μg/ml,p = 0.006,I = 92%)和终末消除半衰期延长(MD = 0.49 小时,p < 0.0001,I = 3%)。其余 36 种药物和 2 种补充剂被纳入系统评价。总体而言,53 种药物和补充剂中的 18 种显示术后 PK 参数发生变化。
本研究表明实践中的异质性,并不能为大多数 PK 参数得出结论性发现。需要前瞻性研究来为最佳实践提供信息,并在减重手术后提高患者的医疗保健和安全性。